Sartorius Stedim BioOutsource offers assays for testing biosimilarity of biologics

Published: 23-Mar-2016
Analysis

New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data

Sartorius Stedim Biotech (SSB) has added new ready-to-use assays for testing Actemra, Stelara and Lucentis biosimilars to its portfolio.

The new assays, launched by SSB’s subsidiary Sartorius Stedim BioOutsource, will allow biopharma manufacturers to generate accurate comparability results rapidly and cost-effectively, the firm says.

The new products include: Actemra IL-6R neutralisation bioassays; an Actemra IL-6R binding ELISA; Stelara IL-12/IL-23 binding assays; a Stelara C1q binding assay; a Stelara neutralisation bioassay; Lucentis VEGF binding assays and a Lucentis VEGF neutralisation bioassay.

They complement BioOutsource’s existing portfolio of assays and expand the number of molecules the company can now support to more than nine.

BioOutsource also has its own in-house R&D department and is continually adding to its portfolio of assays. Therefore, if an assay is not listed, scientists can contact the firm to discuss its availability, or use the company’s expert services to configure an assay to meet their specific requirements.

  • Companies:
  • Sartorius
See more

You may also like

Analysis

Sartorius and TheWell Bioscience partner to develop optimised 3D advanced cell models

Read more
3D advanced models can mimic the organisation and function of cells in living organisms, facilitating more accurate predictions of drug efficacy and toxicity in humans

Trending Articles

  1. Edward Rayner appointed as as Non-Executive Director of Sphere Fluidics Ed’s appointment will strengthen the company’s strategic vision as it progresses ambitious plans for future growth and commercial success
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Meeting new USP Chapter 41 requirements Balances are the essential means by which all therapeutics are ultimately supplied in safe dosages. Dirk Ahlbrecht, Sartorius Group, looks at how to ensure measurements are both accurate and up to new USP standards
  3. Shimadzu’s new Nexera XS inert UHPLC The Nexera XS inert achieves reduced sample loss and excellent peak shape with reproducibly high sensitivity, high-quality and reliable data
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Plastic versus glass in the lab Plastics are now a viable alternative to glass for containers in the laboratory, not least for their resilience to breakage and low extractable profile.
  5. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Analysis

Sartorius and TheWell Bioscience partner to develop optimised 3D advanced cell models

3D advanced models can mimic the organisation and function of cells in living organisms, facilitating more accurate predictions of drug efficacy and toxicity in humans
Finance

MarkHerz and Polyplus collaborate to advance CGT process standards and lower costs

Polyplus (part of Sartorius) has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz, to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product
Manufacturing

Sartorius Stedim Biotech launches new Sartocheck 5 Plus Filter Tester

Designed for use in downstream processing, this new integrity tester is the latest development in the established line of Sartocheck units
Manufacturing

Integrated tools for upstream process intensification: Part II

Changes to bioprocessing methodologies in the biopharmaceutical industry are being driven by the need for increased speed, a lower cost of goods (COGs) and greater flexibility. Faster development times are required to progress biologics and vaccines more rapidly into clinical development and then to market to improve worldwide accessibility
Finance

Sartorius reports double-digit growth in 2018

Full year financials show a 13.2% increase in sales revenue to €1.5 billion
Analysis

Sartorius introduces NBE characterisation services

New biological entities testing is available as off-the-shelf or custom assays for more complex proteins
Containment

Sartorius introduces mini microcarrier bioreactor

New vessel for ambr 250 high throughput system is designed to enable cost-effective, scalable process development of vaccines in cell culture
Subscribe now